- Home
- ETNB vs ADNT Comparison
ETNB vs ADNT Comparison
Compare ETNB & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- ADNT
- Stock Information
- Founded
- ETNB 2018
- ADNT 2016
- Country
- ETNB United States
- ADNT Ireland
- Employees
- ETNB N/A
- ADNT N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- ADNT Auto Parts:O.E.M.
- Sector
- ETNB Health Care
- ADNT Consumer Discretionary
- Exchange
- ETNB Nasdaq
- ADNT Nasdaq
- Market Cap
- ETNB 1.0B
- ADNT 1.1B
- IPO Year
- ETNB 2019
- ADNT N/A
- Fundamental
- Price
- ETNB $7.70
- ADNT $14.68
- Analyst Decision
- ETNB Strong Buy
- ADNT Hold
- Analyst Count
- ETNB 9
- ADNT 10
- Target Price
- ETNB $27.25
- ADNT $18.00
- AVG Volume (30 Days)
- ETNB 1.5M
- ADNT 1.3M
- Earning Date
- ETNB 05-01-2025
- ADNT 05-07-2025
- Dividend Yield
- ETNB N/A
- ADNT N/A
- EPS Growth
- ETNB N/A
- ADNT N/A
- EPS
- ETNB N/A
- ADNT N/A
- Revenue
- ETNB N/A
- ADNT $14,384,000,000.00
- Revenue This Year
- ETNB N/A
- ADNT N/A
- Revenue Next Year
- ETNB N/A
- ADNT $0.83
- P/E Ratio
- ETNB N/A
- ADNT N/A
- Revenue Growth
- ETNB N/A
- ADNT N/A
- 52 Week Low
- ETNB $4.16
- ADNT $10.04
- 52 Week High
- ETNB $11.84
- ADNT $31.19
- Technical
- Relative Strength Index (RSI)
- ETNB 53.47
- ADNT 67.80
- Support Level
- ETNB $7.40
- ADNT $11.89
- Resistance Level
- ETNB $8.92
- ADNT $13.07
- Average True Range (ATR)
- ETNB 0.54
- ADNT 0.61
- MACD
- ETNB 0.13
- ADNT 0.31
- Stochastic Oscillator
- ETNB 53.88
- ADNT 95.53
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.8 billion in fiscal 2024 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2024 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.7 billion but will likely be below $14 billion in fiscal 2025 on tariff interruptions and divesting some lower-quality business.